[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558360":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":10,"maxAge":63,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Children's Hospital, Zurich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Hematological malignancy",null,"Patients witha diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma",[13],{"name":14,"affiliation":15,"role":16},"Jean-Pierre Bourquin, MD, PhD","University Children's Hospital Zurich","STUDY_CHAIR",[18,22],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","0041 44 2667304","Jean-Pierre.Bourquin@kispi.uzh.ch",{"name":23,"role":19,"phone":24,"phoneExt":10,"email":25},"Fabio Steffen, PhD","0041 44 510 74 58","fabio.steffen@kispi.uzh.ch",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University Children's Hospital Zurich","RECRUITING","Zurich","Canton of Zurich","8032","Switzerland","CH",{"type":36,"coordinates":37},"Point",[38,39],8.55,47.36667,{"lat":39,"lon":38},[42,46,49,50,51],{"name":43,"role":19,"phone":44,"phoneExt":10,"email":45},"Beat Bornhauser, PhD","0041 442497055","Beat.Bornhauser@kispi.uzh.ch",{"name":47,"role":48,"phone":10,"phoneExt":10,"email":10},"Nastassja Scheidegger, MD","SUB_INVESTIGATOR",{"name":23,"role":48,"phone":10,"phoneExt":10,"email":10},{"name":43,"role":48,"phone":10,"phoneExt":10,"email":10},{"name":14,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100558360","drug-response-profiling-drp-registry-zurich-for-hematological-malignancies-100558360",false,"NCT06550102","Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies","DRP_ZH","Inclusion Criteria:\n\n* Pediatric and adult patients below the age of 40 years\n* Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma\n* Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research\n* Patient and\u002For guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.\n\nExclusion Criteria:\n\n* Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research","ALL","40 Years",{"count":65,"type":66},1000,"ESTIMATED","10 Years","OBSERVATIONAL","This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.",[71],"Hematological Malignancies",[73,74,75,76],"registry","DRP","acute lymphoblastic leukemia","blood cancer","2024-08-12",{"date":79,"type":80},"2024-08-15","ACTUAL",{"date":82,"type":80},"2022-01-04",{"date":84,"type":66},"2031-12-31",{"name":5,"class":6},1]